AbbVie to acquire Capstan Therapeutics for $2.1 billion
Capstan's lead asset, CPTX2309, is a targeted lipid nanoparticle (tLNP) that delivers an mRNA encoding an anti-CD19 chimeric antigen receptor (CAR) to CD8-expressing cytotoxic T cells in vivo
Capstan's lead asset, CPTX2309, is a targeted lipid nanoparticle (tLNP) that delivers an mRNA encoding an anti-CD19 chimeric antigen receptor (CAR) to CD8-expressing cytotoxic T cells in vivo
Extended lab space for product development, customer demos, and training
The approval is based on a comprehensive package of analytical, nonclinical, and clinical data
Viatel bioresorbable polymers are increasingly used in dental and orthopedic implants
Changhua site meets international regulatory standards for global medical applications
J B Chemicals and Pharmaceuticals receives ANDA approval for Amitriptyline Hydrochloride Tablets from USFDA
The Swiss peptide and oligonucleotide manufacturers roll out major investments across site networks in US, UK and Switzerland
This collaboration ensures that patients receive comprehensive care, including emotional and psychological support throughout their fertility journey
The program will start with providing bTrastuzumab to cancer patients facing treatment delays due to budget constraints
Subscribe To Our Newsletter & Stay Updated